9 Cannabis Company Updates You Need To Know

The Canadian cannabis sector has been trending higher and came off its recent lows. This has caught the attention of cannabis investors and we are closely monitoring how the sector trades this week.

Over the last week, several significant company announcements have been reported and today, we have highlighted nine important company updates that cannabis investors need to be aware of.

Emerald Health and Village Farms: A Dynamic Duo

Zynerba Announces Negative Top-Line Results

GW Pharmaceuticals (GWPH) is an industry leader for a reason…

Developing cannabis-based pharmaceutical treatments is not as easy as it looks and Zynerba Pharmaceuticals (ZYNE) is learning that the hard way.

Zynerba is trading considerably lower after reporting negative top-line results from its double-blind placebo controlled Phase 2 clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with focal seizures.

Biotech Earnings, Updates, and a Major Acquisition Closes

Medical cannabis has the potential to improve the daily lives of millions of people throughout the world. For that reason alone, the biotech sector will be one of the greatest beneficiaries of the legal cannabis movement.

Medical cannabis has the ability to treat countless debilitating and untreatable conditions and this has pharmaceutical companies scared. We expect to see several acquisitions within this space over the next year and have already identified several candidates.

Biotech Stocks Continues To Climb Higher

Although Canadian companies levered to the emerging legal cannabis industry stole the headlines yesterday, Nasdaq-traded biotech firms focused on cannabis-based treatments continued to announce important developments.

Two companies on our watch list, Insys Therapeutics (INSY) and Zynerba Pharmaceuticals (ZYNE) were two of the biggest movers yesterday, rallying 7.7% and 4.4%, respectively.

New President and CEO Send Shares Higher

Cannabis Stock Trends and Opportunities: Finding Value in a Down Market

Despite favorable state-wide election results, concerns among cannabis investors have increased and cannabis stocks continue to move lower following an overextended industry wide rally as well as highly questionable cabinet nominations by president elect Donald Trump.

Although the recent downward trend is concerning, this weakness has created an opportunity for investors to purchase high quality cannabis investments at a considerable discount.

3 Overlooked Benefits of Cannabis that Could Improve Life for Millions

Biotech stocks levered to the cannabis industry have been trading soft over the last month following the DEA’s decision not to reschedule cannabis out of its current Schedule I status.Even though marijuana clearly has medical benefits, it remains a Schedule I substance alongside heroin, LSD, ecstasy, and bath salts under the Controlled Substances Act (CSA). According to the United States Drug Enforcement Agency, Schedule I substances have the following characteristics: